Adalimumab vs Methotrexate for the Treatment of Chronic Plaque Psoriasis. Opinion from JAMA Dermatology Adalimumab vs Methotrexate for the Treatment of Chronic Plaque PsoriasisReply. Psoriasis is a common, chronic, inflammatory skin disease that can have a significant impact on the quality of life of those who are afflicted. Recently released data from large, randomized clinical trials suggests that adalimumab has significant efficacy for the treatment of chronic plaque psoriasis and is well tolerated. In controlled trials, the rates of infections were not different from those in patients treated with placebo or methotrexate (Moreland et al 2002; Mease et al 2000; Gaylor and Duvic 2004). Clinical and histological response of subject in phase II study of adalimumab after 12 weeks.
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Biologic therapies such as adalimumab, a tumour necrosis factor antagonist, are safe and effective in the treatment of moderate to severe chronic plaque psoriasis. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. We sought to determine the efficacy and safety of transitioning to adalimumab for the treatment of psoriasis in patients with suboptimal response to prior therapy with etanercept, methotrexate (MTX), or narrowband (NB)-ultraviolet (UV)B phototherapy. In this 16-week, open-label, phase IIIb trial, patients with chronic plaque psoriasis discontinued suboptimal therapy between 11 and 17 days (etanercept) or between 4 and 10 days (MTX and NB-UVB) before initiating adalimumab (80 mg at week 0, then 40 mg every other week from week 1). Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. Patients with less acute disease can be treated with acitretin or methotrexate as first-line agents.
Its use has been studied extensively for its safety and efficacy profile in the clinical setting. Humira provided faster and more complete clinical disease responses compared with methotrexate as treatment for plaque psoriasis, according to recently published study results. Researchers conducted an assessor-blind clinical trial of 30 patients between the ages of 18 years and 85 years with chronic plaque-type psoriasis who were treated at the outpatient dermatology center of Tufts Medical. Study: Humira provides faster clinical disease response vs. methotrexate for treatment of psoriasis. Few studies exist that evaluate the therapeutic response among switchers of tumor necrosis antagonists in patients with psoriasis, especially Asian patients. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Efficacy And Safety Results From The Randomized Controlled Comparative Study Of Adalimumab Vs. Methotrexate Vs. Placebo In Patients With Psoriasis
In contrast, psoriasis is a chronic condition requiring lifelong therapy. Results show HUMIRA is safe and effective for the treatment of severe chronic plaque psoriasis in pediatric. – HUMIRA is the only biologic approved in Europe for children and adolescents from four years of age with severe chronic plaque psoriasis who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. NORTH CHICAGO, Illinois, June 9, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) announced new results from a pivotal Phase 3 study of HUMIRA (adalimumab) demonstrating significant and clinically meaningful efficacy over methotrexate in children and adolescents with severe chronic plaque psoriasis. Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. The proportion of subjects achieving a PASI 75 response, standard dose versus MTX. Contraindication for treatment with MTX during the study; 5. Adalimumab Effective for Children, Teens With Chronic Plaque Psoriasis That Failed Methotrexate: Presented at EADV. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA is also used to reduce signs and symptoms and to achieve clinical remission in these adults who have lost response to or are unable to tolerate infliximab.